PATENT CLAIM ANALYSIS

Application Number: 16013552
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "134100"]

Abstract:
Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin associated proteins. In some embodiments, the disclosed formulations are applied to the para orbital or periorbital region of a patient to delay or stop the progression of dry macular degeneration. The methods described herein do not involve a direct injection into the eye or subconjunctival region, thus significantly easing both comfort and administration related complications and further preserving barrier functions of retinal layers while also delaying or ceasing the degenerative process to wet conversion.

Claim (Index 7):
The method of  claim 1 , wherein the conventional dosing ranges between 5-400 units.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 94.0
- Lexical Diversity: 1.45977
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13695287', '15485997', '14746221', '13246527', '14970459']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7479322915943178
- 35 USC 102 Novelty (BERT): 0.5185977105485325
- Combined Prediction Score: 0.7249988334897394
- Mean Citation Score: 275.691974
- Max Citation Score: 284.5592
- Similarity Product: 191.8310702183724

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test